Brief: Kiromic BioPharma Reports Favorable Safety, Tolerability, And Early Efficacy From Third Patient In Deltacel-01 Clinical Trial
02/04/2024 15:10
April 2 (Reuters) - Kiromic BioPharma Inc KRBP.PK :
* KIROMIC BIOPHARMA REPORTS FAVORABLE SAFETY, TOLERABILITY,
AND
EARLY EFFICACY FROM THIRD PATIENT IN DELTACEL-01 CLINICAL TRIAL
Source text for Eikon: ID:nBw3PF2kba
Further company coverage: KRBP.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kiromic Biopharma
See all newsBrief: Kiromic Biopharma Files For Offering Up To 1 Million Units
Brief: Kiromic Biopharma Applies To List Common Stock On The NYSE American Under Symbol 'KRBP'
Brief: Kiromic Biopharma Advances Deltacel-01 Into Expansion Phase Following Safety Monitoring Committee's Unanimous Recommendation
Brief: Kiromic Biopharma Reports Favorable Results At Six Weeks From Fourth Patient In Deltacel-01 Clinical Trial
Brief: Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site